Karo Pharma divests brand portfolio to Evolan Pharma
Karo Pharma AB (“Karo”) today announces the divestment of a portfolio consisting of 12 brands to Evolan Pharma AB (“Evolan”). The transaction is effective per today, July 1[st], 2021.Following the acquisitions of recent years, Karo has carried out a strategic evaluation of its products in order to streamline and optimize its commercial portfolio. As an outcome of that evaluation, 12 brands (Citodon, Morfin Special, Sincon, Bamse, Oliva, Karbasal, Complete, Nazamer, Ferromax, Tussin, Samin and Conotrane) have been identified, which are not in line with our growth strategy. Subsequently, Karo